Citius Oncology Inc. announced it has entered into an exclusive distribution agreement with Uniphar, an international healthcare services company, to support access to LYMPHIR (denileukin diftitox-cxdl) outside the United States. Under the agreement, Uniphar will act as the exclusive distribution partner for LYMPHIR in designated territories across Western and Eastern Europe through country-specific managed access programs, subject to local regulations. This marks the third international distribution partnership for Citius Oncology as part of its global expansion strategy. LYMPHIR is not approved for commercial use outside the United States and will be provided in these territories only through managed access programs, which do not constitute marketing authorization or a commercial launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.